Mode
Text Size
Log in / Sign up
N/A N=5 Treatment

Auditory Brainstem Implantation in Young Children

Developmental Cochlear Nerve Deficiency · Acquired Cochlear Nerve Deficiency · Cochlear Aplasia · Post-meningitis Cochlear Ossification · Cochlear Malformation

Enrolled (actual)
5
Serious AEs
40.0%
Results posted
Jun 2018
Primary outcome: Primary: Number of ABI Complications — 2 Events

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Auditory Brainstem Implantation in Children (Device)
Age
Pediatric · 0+ yrs
Sex
All
Sponsor
University of North Carolina, Chapel Hill
Primary completion
Oct 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of ABI Complications
2
SECONDARY
The Oral and Written Language Scales (OWLS) Listening Comprehension Score
77; 46; 40; 40; 62
SECONDARY
The Oral and Written Language Scales (OWLS) Oral Expression Score
48; 50; 40; 40; 58
SECONDARY
Goldman-Fristoe Test of Articulation Scores (GFTA)
SECONDARY
MacArthur-Bates Communicative Development Inventories (CDIs) Score
SECONDARY
Percentage of Correctly Produced Items From the Identifying Early Phonological Needs in Children With Hearing Loss (IEPN) Test-Vocalize on Demand
100; 100; 100; 0; 100; 100
SECONDARY
Percentage of Correctly Produced Items From the Identifying Early Phonological Needs in Children With Hearing Loss (IEPN) Test-Syllables
40; 80; 92; 0; 40; 80
SECONDARY
Percentage of Correctly Produced Items From the Identifying Early Phonological Needs in Children With Hearing Loss (IEPN) Test-Initial Consonants
63; 95; 100; 0; 66; 75
SECONDARY
Percentage of Correctly Produced Items From the Identifying Early Phonological Needs in Children With Hearing Loss (IEPN) Test-Vowels
12; 31; 53; 0; 12; 26
SECONDARY
Percentage of Correctly Produced Items From the Identifying Early Phonological Needs in Children With Hearing Loss (IEPN) Test-Manner Cues
18; 54; 56; 0; 24; 24
SECONDARY
Percentage of Correctly Produced Items From the Identifying Early Phonological Needs in Children With Hearing Loss (IEPN) Test-Final Consonants
29; 64; 94; 0; 0; 0
SECONDARY
Percentage of Correctly Produced Items From the Identifying Early Phonological Needs in Children With Hearing Loss (IEPN) Test-Place Cues
20; 58; 58; 0; 27; 27
SECONDARY
Percentage of Correctly Produced Items From the Identifying Early Phonological Needs in Children With Hearing Loss (IEPN) Test-Voice Cues
16; 67; 90; 0; 41; 25
SECONDARY
Change in Speech Perception Test Battery Scores-Detection Audiogram
30; 42; 30; 120; 47; 35
SECONDARY
Speech Perception Test Battery Scores-IT-MAIS or MAIS
3; 43; 32; 42; 0; 28
SECONDARY
Change in Speech Perception Test Battery Scores-Ling Sound Test
100; 100; 100; 0; 100; 100
SECONDARY
Change in Speech Perception Test Battery Scores-ESP Low Verbal
25; 58; 25; 100; 75; 67
SECONDARY
Change in Speech Perception Test Battery Scores-ESP Standard
70; 62; 50; 41; 66; 41
SECONDARY
Pre-School Language Scale (PLS-5) Scores

Summary

To purpose of this feasibility study is to demonstrate the safety and efficacy of the Nucleus 24 Multichannel Auditory Brainstem Implant (ABI, Cochlear Corp, Sydney, AUS) in children without the diagnosis of neurofibromatosis type II (NFII) that have either experienced failed cochlear implantation (CI) or have been unable to receive a CI secondary to cochlear or cochlear nerve disorders. These conditions can include: developmental or acquired cochlear nerve deficiency (CND), cochlear aplasia (Michel), post-meningitic cochlear ossification or cochlear malformation. This study proposes to implant up to 10 young children (<5 yrs. of age) with the Nucleus 24 Multichannel ABI (Sydney, AUS) in an attempt to demonstrate safety of the surgical procedure, tolerance of device stimulation, and the potential for auditory benefit beyond that experienced with their CI. This study will provide the preliminary experience for a larger scale clinical trial. Aim 1: Demonstrate the safety of ABI surgery in children. Aim 2: Demonstrate the development of sound awareness and improved speech understanding among children implanted with the ABI when compared to their baseline skills. Aim 3: Demonstrate the development of oral language skills following the use of the ABI that were not evident prior to its use.

Eligibility Criteria

Inclusion Criteria

  • Pre-linguistic hearing loss (birth-5 yrs.; age at ABI 18 months-5yrs) with both:
  • MRI +/- CT evidence of one of the following: Cochlear nerve deficiency, Cochlear aplasia or severe hypoplasia, Severe inner ear malformation, Post-meningitis ossification
  • When a cochlea is present or patent, lack of significant benefit from CI despite consistent use (>6 mo.)
  • Post-linguistic hearing loss (<18 yrs. of age) with both:
  • Loss or lack of benefit from appropriate CI without the possibility for revision or contralateral implantation. Examples might include: Post-meningitis ossification, Bilateral temporal bone fractures with cochlear nerve avulsion, Failed revision CI without benefit
  • Previously developed open set speech perception and auditory-oral language skills
  • No medical contraindications
  • Willing to receive the appropriate meningitis vaccinations
  • No or limited cognitive/developmental delays which would be expected to interfere with the child's ability to cooperate in testing and/or programming of the device, in developing speech and oral language, or which would make an implant and subsequent emphasis on aural/oral communication not in the child's best interest
  • Strong family support including language proficiency of the parent(s) in the child's primary mode of communication as well as written and spoken English.
  • Reasonable expectations from parents including a thorough understanding:
  • of potential benefits and limitations of ABI
  • of parental role in rehabilitation
  • that the child may not develop spoken language as a primary communication mode or even sufficient spoken language to make significant academic progress in an aural/oral environment
  • Involvement in an educational program that emphasizes development of auditory skills with or without the use of supplementary visual communication.
  • Able to comply with study requirements including travel to investigation sites.
  • Informed consent for the procedure from the child's parents/legal guardian.

Exclusion Criteria

  • Pre- or post-linguistic child currently making significant progress with CI
  • MRI evidence of one of the following:
  • normal cochlea and cochlear nerves or NFII
  • brainstem or cortical anomaly that makes implantation unfeasible
  • Clear surgical reason for poor CI performance that can be remediated with revision CI or contralateral surgery rather than ABI.
  • Intractable seizures or progressive, deteriorating neurological disorder
  • Unable to participate in behavioral testing and mapping with their CI. If this appears to be an age effect, ABI will be delayed until we can be assured that the child will be able to participate, as reliable objective measures of mapping are currently not available for mapping these devices.
  • Lack of potential for spoken language development. This will be considered the case when evidence of the following exist:
  • Severe psychomotor retardation, autism, cerebral palsy, or developmental delays beyond speech that would preclude usage of the device and oral educational development. Autism is a special case where there is the potential for delayed presentation. When early signs are considered present, our group routinely requests a comprehensive developmental assessment for further evaluation prior to considering routine evaluation. A specialized group is readily available at our institution for such an evaluation.
  • Unable to tolerate general anesthesia (cardiac, pulmonary, bleeding diathesis, etc.).
  • Need for brainstem irradiation
  • Unrealistic expectations on the part of the subject/family regarding the possible benefits, risks and limitations that are inherent to the procedure and prosthetic device.
  • Unwilling to sign the informed consent.
  • Unwilling to make necessary follow-up appointments.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01904448). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search